NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.89 -0.02 (-2.20 %) (As of 12/6/2019 04:04 AM ET) Add Compare Today's Range$0.87Now: $0.89▼$0.9450-Day Range N/A52-Week Range$0.49Now: $0.89▼$4.20Volume77,800 shsAverage Volume287,411 shsMarket Capitalization$16.09 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSEAMERICAN:NAVB Previous SymbolNYSEMKT:NAVB CUSIP63937X10 CIK810509 Webhttp://www.navidea.com/ Phone+1-614-7937500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares18,079,000Market Cap$16.09 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive NAVB News and Ratings via Email Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. AMEX:NAVB Rates by TradingView Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions What is Navidea Biopharmaceuticals' stock symbol? Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB." How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts' consensus estimates of ($0.17). The biopharmaceutical company earned $0.24 million during the quarter. View Navidea Biopharmaceuticals' Earnings History. When is Navidea Biopharmaceuticals' next earnings date? Navidea Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Navidea Biopharmaceuticals. What price target have analysts set for NAVB? 2 equities research analysts have issued 1-year price objectives for Navidea Biopharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $2.50 in the next year. This suggests a possible upside of 180.9% from the stock's current price. View Analyst Price Targets for Navidea Biopharmaceuticals. What is the consensus analysts' recommendation for Navidea Biopharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Navidea Biopharmaceuticals. Has Navidea Biopharmaceuticals been receiving favorable news coverage? Press coverage about NAVB stock has trended negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Navidea Biopharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Navidea Biopharmaceuticals. Are investors shorting Navidea Biopharmaceuticals? Navidea Biopharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,220,000 shares, an increase of 85.7% from the October 31st total of 656,900 shares. Based on an average daily trading volume, of 546,900 shares, the days-to-cover ratio is currently 2.2 days. Currently, 10.5% of the company's stock are sold short. View Navidea Biopharmaceuticals' Current Options Chain. Who are some of Navidea Biopharmaceuticals' key competitors? Some companies that are related to Navidea Biopharmaceuticals include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR). What other stocks do shareholders of Navidea Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Rexahn Pharmaceuticals (REXN), Inovio Pharmaceuticals (INO), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Agenus (AGEN), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP) and SLS International (SLS). Who are Navidea Biopharmaceuticals' key executives? Navidea Biopharmaceuticals' management team includes the folowing people: Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)Dr. Michael Stanley Rosol Ph.D., Chief Medical OfficerErika Gibson, Director of Fin. & Admin.Mr. William J. Regan, Chief Compliance Officer (Age 67)Ms. Sharon Correia, Sr. Director of Corp. Communications How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Navidea Biopharmaceuticals' stock price today? One share of NAVB stock can currently be purchased for approximately $0.89. How big of a company is Navidea Biopharmaceuticals? Navidea Biopharmaceuticals has a market capitalization of $16.09 million. Navidea Biopharmaceuticals employs 14 workers across the globe.View Additional Information About Navidea Biopharmaceuticals. What is Navidea Biopharmaceuticals' official website? The official website for Navidea Biopharmaceuticals is http://www.navidea.com/. How can I contact Navidea Biopharmaceuticals? Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500. MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 167 (Vote Outperform)Underperform Votes: 156 (Vote Underperform)Total Votes: 323MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?
